Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference

Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.

HER2-targeted therapies have evolved rapidly since the arrival of Herceptin (trastuzumab) more than 15 years ago. New therapies, such as Perjeta and Kadcyla, have further improved outcomes, but now we are looking at the best way to use all these treatments and in what sequence.

"It's important for patients to be aware of what the landscape is," he says, so they can have informed discussions with their oncologists on what is the best course of treatment for them.